Edwards Lifesciences Corp. lost more than a fifth of its market value as it turned in the biggest decline on the S&P 500. The company, which makes a less-invasive heart valve, generated an estimated $448 million in sales during the latest quarter, less than the $465 million to $485 million that was estimated in July, the company said.
Edwards Lifesciences stock falls as sales disappoint
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week